PanamaTimes

Monday, Dec 09, 2024

Efficacy of Pfizer’s Covid-19 pill questioned

Efficacy of Pfizer’s Covid-19 pill questioned

An Israeli study has indicated the medication is of little measurable benefit to patients in the 40-65 age bracket
A Covid-19 pill lauded by the World Health Organization (WHO) may be of little or no benefit to patients aged between 40 and 65, a new study by Israeli researchers has suggested. The medication, made by Pfizer and sold under the trade name Paxlovid, has proven effective in those aged over 65, however.

Published in the New England Journal of Medicine on Wednesday, the study involved 109,000 patients who had received Paxlovid. After analyzing different age brackets, the scientists concluded that the treatment did little to improve the conditions of patients aged 40 to 65. At the same time, the medication reduced the number of hospitalizations among seniors by approximately 75%, if given shortly after contracting Covid-19.

The analysis, however, is based on data obtained from the Israeli health system as opposed to observing patients in a randomized study with a control group – something which represents a departure from practices held as the standard for such research, AP pointed out.

No official comment from Pfizer has been forthcoming as of yet.

The US Food and Drug Administration authorized Paxlovid late last year for adults and children over 12 who suffer from chronic conditions like obesity, diabetes and heart disease. According to federal records cited by AP, over 3.9 million prescriptions for the medication have been issued since the drug was given the green light.

The Biden administration has been placing particular emphasis on Paxlovid in the hope of reducing the number of hospitalizations. US authorities are said to have shelled out some $10 billion to procure the drug, which is being made available to the public at thousands of pharmacies through the government’s test-and-treat initiative.

In an emailed statement on Wednesday, White House spokesperson Kevin Munoz cited several other studies which indicate that Paxlovid helps reduce hospitalizations among people 50 and older. That research, however, has yet to be published in peer-reviewed journals, AP noted.

The official was quoted as saying that the “growing body of evidence is showing that individuals between the ages of 50 and 64 can also benefit from Paxlovid.”
Comments

Oh ya 2 year ago
I think I read somewhere it was the liver and kidneys that it also is harmful to. But of you have taken the shot and especially the boosters then this pill is the least of your problems

Newsletter

Related Articles

PanamaTimes
0:00
0:00
Close
Special counsel Jack Smith asks the court to dismiss his appeal against Trump in the Mar-a-Lago classified documents case.
A Chinese retail chain has substituted traditional mannequins with real women walking on treadmills to display their clothes in motion.
Iranian Man Charged in Plot to Assassinate Donald Trump
Vatican Synod Concludes with Support for Women in Leadership Roles
Biden Labels Trump a Threat to Democracy
McDonald's Linked to E. coli Outbreak Leading to One Death
AI Regulation Takes Center Stage in 2024 US Presidential Campaign
Cuba's Power Struggles: Nationwide Blackout Strikes Again
Meta Faces Legal Battle Over Teen Social Media Addiction
UK Government Proposes Weight-Loss Injections to Combat Obesity and Boost Employment
Russia's Call for a BRICS Financial System Alternative
Indigenous Groups in Brazil Protest Carbon Credit Deal
Tesla's Robotaxi Design Strikes Controversy
Boeing to Reduce Workforce by 10% Amid Financial Strain
Brazilian Man Arrested for Decades-long Abuse and Imprisonment of Family
Donald Trump Amplifies Anti-Migrant Sentiments in Colorado Speech
Mass Looting of Chicago Cargo Train: 50 to 150 Looters Ransack Containers in Chaotic Scene
The Impact of Online Culture on Young Women: Survey Insights
Hypersonic Jet to Revolutionize Air Travel
Facilitated Communication: Miracle Tool or Manipulative Method?
US Election 2024: A Deadlock Between Trump and Harris
Dominica Sells Citizenship to Boost Climate Resilience
Elon Musk's X Faces Fines and Account Error in Brazil
Scott Jennings leaves CNN panel speechless as he tears apart Tim Walz's flimsy excuse of being "too dumb to tell the truth."
Earth Faces Severe Geomagnetic Storm from Solar Flare
China-Led Bloc Challenges The Quad in Indo-Pacific Region
Biden-Harris sent forklifts to open the border when Texas built a razor wall.
Storm Helene Devastates Eastern and Midwestern US, Claims 44 Lives
Trump Taps Elon Musk to Lead Federal Spending Cuts, Promising Trillions in Savings
Importing voters: With an election looming, the U.S. is approving citizenship applications at the fastest speed in years.
Hurricane Helene Set to Slam Florida with 'Unsurvivable' Conditions
El Salvadoran President Bukele at the UN: "Some complain that we put thousands in prison. In reality, we set millions free."
Google Commits 120 Million Dollars for Global AI Education: Sundar Pichai
Tennessee Woman Sentenced for Attempted Murder-For-Hire
Amazon Rainforest Suffers Massive Deforestation
Earth's Planetary Boundaries Breached
Elon Musk’s X Circumvents Brazil’s Supreme Court Block
Brazilian Judge Accuses Elon Musk’s X of Circumventing Court-Ordered Ban
Venezuelan Opposition Leader Coerced into Recognizing Maduro's Victory
Brazil's Firefighters Battle Amazon Blazes and Arsonists
X Social Media Platform Ordered Offline Again in Brazil
Global Workdays Required to Afford iPhone 16
In his podcast, Joe Rogan rightly questioned, "YOU NEED A VACCINE PASSPORT FOR FOOD, BUT VOTER ID IS ‘RACIST'?!"
Trump Unveils New Cryptocurrency Venture Amidst Campaign
X Update Enables App to Bypass Brazil Ban, Say Internet Providers
Delta Airlines Sets Strict Wardrobe Guidelines for Flight Attendants
Norway Achieves Milestone in Electric Vehicle Adoption
Hezbollah Hit by Explosive Pagers in Lebanon
Ex-Soldier Describes Trump Assassination Suspect's Troubled Ukraine Stint
Ghislaine Maxwell's Sex-Trafficking Conviction Upheld by Appeals Court
×